ER reactivation therapy for breast cancer (POLLY)
NCT02188745
This multi-center investigator-initiated Phase II study will assess the therapeutic benefit of alternating 17b-estradiol/aromatase inhibitor therapies on a 2-month/4-month schedule for prevention of disease progression.